Abstract
Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are two well-studied lysophospholipids that are known to be important regulators of cellular events. Their actions are mediated by activating a family of G-protein coupled receptors present in many cell types and tissues. These receptors have diverse biological roles owing to the heterogeneity of their signal transduction pathways. Many of these receptors are expressed in subsets of cells in the developing and mature mammalian nervous system and are thought to have important functions in its formation and maintenance. They are also widely expressed within other organ systems such as the immune system. Growing interest in the field has stimulated the development of a number of molecules that act as agonists or antagonists to LPA and S1P receptors. These molecules may lead to the development of new therapeutic compounds. Indeed, one such compound (FTY720) is currently in clinical trials for use in preventing transplant rejection and treating multiple sclerosis. The purpose of this manuscript is to: 1) review effects elicited by LPA and S1P on cells and tissues with a particular emphasis on the nervous system, 2) examine possible roles of these lipids in the development of disease, and 3) summarize the existing literature describing their agonists/antagonists.
Keywords: lysophosphatidic acid, sphingosine 1-phosphate, nervous system, agonists, antagonists, immune regulation, multiple sclerosis, pain
Current Drug Targets
Title: Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Volume: 8 Issue: 1
Author(s): D. R. Herr and J. Chun
Affiliation:
Keywords: lysophosphatidic acid, sphingosine 1-phosphate, nervous system, agonists, antagonists, immune regulation, multiple sclerosis, pain
Abstract: Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are two well-studied lysophospholipids that are known to be important regulators of cellular events. Their actions are mediated by activating a family of G-protein coupled receptors present in many cell types and tissues. These receptors have diverse biological roles owing to the heterogeneity of their signal transduction pathways. Many of these receptors are expressed in subsets of cells in the developing and mature mammalian nervous system and are thought to have important functions in its formation and maintenance. They are also widely expressed within other organ systems such as the immune system. Growing interest in the field has stimulated the development of a number of molecules that act as agonists or antagonists to LPA and S1P receptors. These molecules may lead to the development of new therapeutic compounds. Indeed, one such compound (FTY720) is currently in clinical trials for use in preventing transplant rejection and treating multiple sclerosis. The purpose of this manuscript is to: 1) review effects elicited by LPA and S1P on cells and tissues with a particular emphasis on the nervous system, 2) examine possible roles of these lipids in the development of disease, and 3) summarize the existing literature describing their agonists/antagonists.
Export Options
About this article
Cite this article as:
Herr R. D. and Chun J., Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315669
DOI https://dx.doi.org/10.2174/138945007779315669 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Anti-Cancer Targeting Telomerase Inhibitors: β-Rubromycin and Oleic Acid
Mini-Reviews in Medicinal Chemistry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Recent Update on Pharmacokinetics and Drug Metabolism in CNS-based Drug Discovery
Current Pharmaceutical Design Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells
Current Topics in Medicinal Chemistry Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Design, Synthesis, Biological Evaluation and Molecular Docking Studies of 5-fluorouracil-dithiocarbamate Conjugates
Letters in Drug Design & Discovery Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Current Topics in Medicinal Chemistry